The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. The centre is hosted on Elsevier Connect and grants permission for all COVID-19-related research to be immediately available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights. Guangdong Second Provincial General Hospital has implemented an observing system in negative pressure isolation wards to monitor and control infection, ensuring the safety of medical staff. This system includes real-time monitoring and immediate intervention to prevent nosocomial infections. The hospital plans to integrate artificial intelligence image recognition to enhance the system's sensitivity and accuracy. Convalescent plasma therapy has shown promise in treating various viral infections, and its potential use in COVID-19 treatment is discussed, highlighting its safety and efficacy. Additionally, the article explores the combination of antiviral and anti-inflammatory treatments, suggesting baricitinib as a promising candidate due to its JAK inhibitor properties and acceptable side-effect profile.The COVID-19 Resource Centre, established by Elsevier in January 2020, provides free information in English and Mandarin on the novel coronavirus. The centre is hosted on Elsevier Connect and grants permission for all COVID-19-related research to be immediately available in PubMed Central and other public repositories, with unrestricted reuse and analysis rights. Guangdong Second Provincial General Hospital has implemented an observing system in negative pressure isolation wards to monitor and control infection, ensuring the safety of medical staff. This system includes real-time monitoring and immediate intervention to prevent nosocomial infections. The hospital plans to integrate artificial intelligence image recognition to enhance the system's sensitivity and accuracy. Convalescent plasma therapy has shown promise in treating various viral infections, and its potential use in COVID-19 treatment is discussed, highlighting its safety and efficacy. Additionally, the article explores the combination of antiviral and anti-inflammatory treatments, suggesting baricitinib as a promising candidate due to its JAK inhibitor properties and acceptable side-effect profile.